Abstract
Extracorporeal membrane oxygenation (ECMO) is one of the primary reasons systemic hypertension is experienced in hospitalized neonates. Commonly used antihypertensive agents have resulted in significant adverse effects in neonatal and pediatric populations. Nicardipine is a desirable option because of its rapid and titratable antihypertensive properties and low incidence of adverse effects. However, data for use in neonatal ECMO are limited. We conducted a retrospective review of patients less than 44 weeks post-menstrual age who received a nicardipine infusion for first-line treatment of systemic hypertension while on ECMO at our institution between 2010 and 2016. Systolic (SBP), diastolic (DBP), and mean arterial (MAP) blood pressures were evaluated for 48-h after nicardipine initiation. Eight neonates received a nicardipine infusion while on ECMO during the study period. Nicardipine was initiated at a mean dose of 0.52 ( ± 0.22) mcg/kg/min and titrated to a maximum dose of 1.1 ( ± 0.85) mcg/kg/min. The median duration of nicardipine use was 51 (range 4–227) hours. Significant decreases in SBP, DBP, and MAP occurred within one hour of initiation of nicardipine and were sustained through the majority of the 48-h evaluation period. No patients experienced hypotension. Prospective studies are warranted to evaluate the optimal dose, safety, and efficacy of nicardipine in neonates who require ECMO.
Similar content being viewed by others
References
Blowey DL, Duda PJ, Stokes P, Hall M (2011) Incidence and treatment of hypertension in the neonatal intensive care unit. J Am Soc Hypertens 5:478–483
Batisky DL (2014) Neonatal hypertension. Clin Perinatol 41:529–542
Boedy RF, Goldberg AK, Howell CG Jr, Hulse E, Edwards EG, Kanto WP Jr (1990) Incidence of hypertension in infants on extracorporeal membrane oxygenation. J Pediatr Surg 25:258–261
Becker JA, Short BL, Martin GR (1998) Cardiovascular complications adversely affect survival during extracorporeal membrane oxygenation. Crit Care Med 26:1582–1586
Sell LL, Cullen ML, Lerner GR, Whittlesey GC, Shanley CJ, Klein MD (1987) Hypertension during extracorporeal membrane oxygenation: cause, effect, and management. Surgery 102:724–730
Heggen JA, Fortenberry JD, Tanner AJ, Reid CA, Mizzell DW, Pettignano R (2004) Systemic hypertension associated with venovenous extracorporeal membrane oxygenation for pediatric respiratory failure. J Pediatr Surg 39:1626–1631
Ku LC, Zimmerman K, Benjamin DK, Clark RH, Hornik CP, Smith PB (2017) Safety of enalapril in infants admitted to the neonatal intensive care unit. Pediatr Cardiol 38:155–161
Tack ED, Perlman JM (1988) Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr 112:805–810
Perlman JM, Volpe JJ (1989) Neurologic complications of captopril treatment of neonatal hypertension. Pediatrics 83:47–52
Moffett BS, Price JF (2008) Evaluation of sodium nitroprusside toxicity in pediatric cardiac surgical patients. Ann Pharmacother 42:1600–1604
Hammer GB, Lewandowski A, Drover DR, Rosen DA, Cohen C, Anand R et al (2015) Safety and efficacy of sodium nitroprusside during prolonged infusion in pediatric patients. Pediatr Crit Care Med 16:397–403
Radford D (1983) Side effects of verapamil in infants. Arch Dis Child 58:465–466
Garland JS, Berens RJ, Losek JD, Wilson AD (1985) An infant fatality following verapamil therapy for supraventricular tachycardia: cardiovascular collapse following intravenous verapamil. Pediatr Emerg Care 1:198–200
Kirk CR, Gibb JL, Thomas R, Radley-Smith R, Qureshi SA (1987) Cardiovascular collapse after verapamil in supraventricular tachycardia. Arch Dis Child 62:1265–1266
Flynn JT, Tullus K (2009) Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol 24:1101–1112
Treluyer JM, Hubert P, Jouvet P, Couderc S, Cloup M (1993) Intravenous nicardipine in hypertensive children. Eur J Pediatr 152:712–714
Gouyon JB, Geneste B, Semama DS, Françoise M, Germain JF (1997) Intravenous nicardipine in hypertensive preterm infants. Arch Dis Child Fetal Neonatal Ed 76:F126–F127
Milou C, Debuche-Benouachkou V, Semama DS, Germain JF, Gouyon JB (2000) Intravenous nicardipine as a first-line antihypertensive drug in neonates. Intensive Care Med 26:956–958
Fanaroff JM, Fanaroff AA (2006) Blood pressure disorders in the neonate: hypotension and hypertension. Semin Fetal Neonatal Med 11:174–181
Malesker MA, Hilleman DE (2012) Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically ill patients. J Crit Care 27:528.e7–14
Halpern NA, Goldberg M, Neely C, Sladen RN, Goldberg JS, Floyd J et al (1992) Postoperative hypertension: a multicenter, prospective, randomized comparison between intravenous nicardipine and sodium nitroprusside. Crit Care Med 20:1637–1643
Bebawy JF, Houston CC, Kosky JL, Badri AM, Hemmer LB, Moreland NC et al (2015) Nicardipine is superior to esmolol for the management of postcraniotomy emergence hypertension: a randomized open-label study. Anesth Analg 120:186–192
Vecht RJ, Swanson KT, Nicolaides EP, Lennox SC, Gibson DG (1989) Comparison of intravenous nicardipine and nitroglycerin to control systemic hypertension after coronary artery bypass grafting. Am J Cardiol 64:19H–21H
Flynn JT, Mottes TA, Brophy PD, Kershaw DB, Smoyer WE, Bunchman TE (2001) Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr 139:38–43
McBride BF, White CM, Campbell M, Frey BM (2003) Nicardipine to control neonatal hypertension during extracorporeal membrane oxygen support. Ann Pharmacother 37:667–670
Tobias JD, Pietsch JB, Lynch A (1996) Nicardipine to control mean arterial pressure during extracorporeal membrane oxygenation. Paediatr Anaesth 6:57–60
Levene MI, Gibson NA, Fenton AC, Papathoma E, Barnett D (1990) The use of a calcium-channel blocker, nicardipine, for severely asphyxiated newborn infants. Dev Med Child Neurol 32:567–574
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent
For this type of study, formal consent is not required. Approval for this study was obtained from the Washington University in St. Louis Institutional Review Board.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Liviskie, C.J., DeAvilla, K.M., Zeller, B.N. et al. Nicardipine for the Treatment of Neonatal Hypertension During Extracorporeal Membrane Oxygenation. Pediatr Cardiol 40, 1041–1045 (2019). https://doi.org/10.1007/s00246-019-02113-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-019-02113-3